Search

Your search keyword '"Maheu, Emmanuel"' showing total 272 results
Start Over Author "Maheu, Emmanuel"
272 results on '"Maheu, Emmanuel"'

55. Development of classification criteria for hand osteoarthritis: comparative analyses of persons with and without hand osteoarthritis

Author

Haugen, Ida K, primary, Felson, David T, additional, Abhishek, Abhishek, additional, Berenbaum, Francis, additional, Bierma-Zeinstra, Sita, additional, Borgen, Tove, additional, Herrero Beaumont, Gabriel, additional, Ishimori, Mariko, additional, Jonsson, Helgi, additional, Kroon, Féline PB, additional, Maheu, Emmanuel, additional, Ramonda, Roberta, additional, Ritschl, Valentin, additional, Stamm, Tanja A, additional, van der Heijde, Desirée, additional, Wittoek, Ruth, additional, Greibrokk, Elsie, additional, Smeets, Wilma, additional, and Kloppenburg, Margreet, additional

Published
2020
Full Text
View/download PDF

56. Cross-cultural translation, adaptation and validation of a Japanese version of the Functional Index for Hand Osteoarthritis (J-FIHOA)

Author

Nakagawa, Yasunobu, primary, Kurimoto, Shigeru, additional, Maheu, Emmanuel, additional, Matsui, Yuichiro, additional, Kanno, Yuri, additional, Menuki, Kunitaka, additional, Hayashi, Masanori, additional, Nemoto, Tetsuya, additional, Nishizuka, Takanobu, additional, Tatebe, Masahiro, additional, Yamamoto, Michiro, additional, Iwatsuki, Katsuyuki, additional, Dreiser, Renée Liliane, additional, and Hirata, Hitoshi, additional

Published
2020
Full Text
View/download PDF

60. Additional file 1 of Cross-cultural translation, adaptation and validation of a Japanese version of the functional index for hand osteoarthritis (J-FIHOA)

Author

Nakagawa, Yasunobu, Kurimoto, Shigeru, Maheu, Emmanuel, Matsui, Yuichiro, Kanno, Yuri, Kunitaka Menuki, Hayashi, Masanori, Nemoto, Tetsuya, Takanobu Nishizuka, Tatebe, Masahiro, Michiro Yamamoto, Iwatsuki, Katsuyuki, Dreiser, Renée Liliane, and Hirata, Hitoshi

Abstract

Additional file 1. Summary points for translation and cultural adaptation.

Published
2020
Full Text
View/download PDF

62. Development of classification criteria for hand osteoarthritis:Comparative analyses of persons with and without hand osteoarthritis

Author

Haugen, Ida K., Felson, David T., Abhishek, Abhishek, Berenbaum, Francis, Bierma-Zeinstra, Sita, Borgen, Tove, Herrero Beaumont, Gabriel, Ishimori, Mariko, Jonsson, Helgi, Kroon, Féline P.B., Maheu, Emmanuel, Ramonda, Roberta, Ritschl, Valentin, Stamm, Tanja A., Van Der Heijde, Desirée, Wittoek, Ruth, Greibrokk, Elsie, Smeets, Wilma, Kloppenburg, Margreet, Haugen, Ida K., Felson, David T., Abhishek, Abhishek, Berenbaum, Francis, Bierma-Zeinstra, Sita, Borgen, Tove, Herrero Beaumont, Gabriel, Ishimori, Mariko, Jonsson, Helgi, Kroon, Féline P.B., Maheu, Emmanuel, Ramonda, Roberta, Ritschl, Valentin, Stamm, Tanja A., Van Der Heijde, Desirée, Wittoek, Ruth, Greibrokk, Elsie, Smeets, Wilma, and Kloppenburg, Margreet

Abstract

Objectives Further knowledge about typical hand osteoarthritis (OA) characteristics is needed for the development of new classification criteria for hand OA. Methods In a cross-sectional multi-centre international study, a convenience sample of patients from primary and secondary/tertiary care with a physician-based hand OA diagnosis (n = 128) were compared with controls with hand complaints due to inflammatory or non-inflammatory conditions (n = 70). We examined whether self-reported, clinical, radiographic and laboratory findings were associated with hand OA using logistic regression analyses. Discrimination between groups was assessed by calculating the area under receiver operating curves (AUC). Results Strong associations with hand OA were observed for radiographic osteophytes (OR = 1.62, 95 CI 1.40 to 1.88) and joint space narrowing (JSN) (OR = 1.57, 95 CI 1.36 to 1.82) in the distal interphalangeal (DIP) joints with excellent discrimination (AUC = 0.82 for both). For osteophytes and JSN, we found acceptable discrimination between groups in the proximal interphalangeal joints (AUC = 0.77 and 0.78, respectively), but poorer discrimination in the first carpometacarpal joints (AUC = 0.67 and 0.63, respectively). Painful DIP joints were associated with hand OA, but were less able to discriminate between groups (AUC = 0.67). Age and family history of OA were positively associated with hand OA, whereas negative associations were found for pain, stiffness and soft tissue swelling in metacarpophalangeal joints, pain and marginal erosions in wrists, longer morning stiffness, inflammatory biomarkers and autoantibodies. Conclusions Differences in symptoms, clinical findings, radiographic changes and laboratory tests were found in patients with hand OA versus controls. Radiographic OA features, especially in DIP joints, were best suited to discriminate between groups.

Published
2020

63. LB-003 - Serum Intestinal Permeability Biomarkers are associated with erosive hand osteoarthritis and radiographic severity: Results: from the DIGICOD cohort.

Author

Binvignat, Marie, Fellahi, Soraya, Bastard, Jean-Philippe, Rousseau, Alexandra, Tuffet, Sophie, Courties, Alice, Pigenet, Audrey, WANHERDRICK, Kristell, Kloppenburg, Margreet, Richette, Pascal, Maheu, Emmanuel, Crema, Michel D., Klatzmann, David, Sokol, Harry, Mariotti-Ferrandiz, Encarnita, Berenbaum, Francis, and Sellam, Jeremie

Published
2024
Full Text
View/download PDF

68. Non-steroidal anti-inflammatory drugs in the pharmacological management of osteoarthritis in the very old: prescribe or proscribe?

Author

Cadet, Christian and Maheu, Emmanuel

Abstract

Osteoarthritis (OA) is the most common form of arthritis worldwide, and ranges in the top 5–10 most disabling diseases. Contrary to common opinion, this disease is severe, often symptomatic, and may lead to loss of mobility and independence, as well as being responsible for increased frailty and excess mortality [standardized ratio: 1.55 (95% confidence interval, CI: 1.41–1.70)]. The incidence of OA increases dramatically with age in an increasingly ageing world. Therefore, practitioners involved in the management of OA often have to manage very old patients, aged 75–80 years and above, as part of their daily practice. Treatment options are limited. In addition to education and physical treatments, which are at the forefront of all treatment recommendations but require a low level of symptoms to be implemented, many pharmacological options are proposed. Nonsteroidal anti-inflammatory drugs (NSAIDs) can be used as a second-line treatment but with great caution. However, the precise incidence of cardiovascular, renal, and gastrointestinal adverse events in very elderly patients is unclear. All of these risks are increased in the elderly. The relative risks can be extrapolated from various studies. However, what is the absolute risk according to age categorization? The answer to this question is important because NSAIDs should be used in very elderly patients with OA only if full information has been provided and the decision to prescribe this treatment is shared between the patient and their doctor. This article reviews the risks and currently available recommendations, and proposes practical options and warnings to allow for a responsible and limited use of NSAIDs in the very old. Plain language summary: NSAIDS in the very Old : Prescribe or Proscribe? Osteoarthritis (OA) in the very old is a serious disease leading to loss of independence, frailty, and excess mortality. Quantitative data from clinical trials and population-based observational studies on the risk of NSAID-related side effects allow the prescriber to provide more accurate information to each patient. If there is no contraindication, the decision to initiate NSAID therapy in a very old OA patient should be made in a shared manner, with the patient fully informed of the risks. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

69. Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements

Author

Migliore, Alberto, primary, Gigliucci, Gianfranco, additional, Alekseeva, Liudmila, additional, Avasthi, Sachin, additional, Bannuru, Raveendhara R, additional, Chevalier, Xavier, additional, Conrozier, Thierry, additional, Crimaldi, Sergio, additional, Damjanov, Nemanja, additional, de Campos, Gustavo Constantino, additional, Diracoglu, Demirhan, additional, Herrero-Beaumont, Gabriel, additional, Iolascon, Giovanni, additional, Ionescu, Ruxandra, additional, Isailovic, Natasa, additional, Jerosch, Jörg, additional, Lains, Jorge, additional, Maheu, Emmanuel, additional, Makri, Souzi, additional, Martusevich, Natalia, additional, Matucci Cerinc, Marco, additional, Micu, Mihaela, additional, Pavelka, Karel, additional, Petrella, Robert J, additional, Tarantino, Umberto, additional, and Raman, Raghu, additional

Published
2019
Full Text
View/download PDF

70. Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids.

Author

Maheu, Emmanuel, Soriot-Thomas, Sandrine, Noel, Eric, Ganry, Hervé, Lespessailles, Eric, and Cortet, Bernard

Abstract

Introduction: Despite their poor tolerance, especially in the elderly, weak opioids (WO) remain commonly prescribed for patients with knee osteoarthritis (KOA). We compared the efficacy and safety of a new wearable transcutaneous electrical nerve stimulation (W-TENS) device with WO for the treatment of moderate-to-severe, nociceptive KOA chronic pain. Methods: The study was a non-inferiority, multicentric, prospective, randomized, single-blind, controlled, 2-parallel groups Trial. A total of 110 patients with KOA were included (Kellgren-Lawrence radiographic grade ⩾2; American College of Rheumatology criteria), with chronic moderate-to-severe nociceptive pain (mean 8-day pain intensity (PI) ⩾ 4 on an 11-point numerical rating scale), in failure to non-opioid analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs). Patients with neuropathic pain were excluded. The co-primary endpoints were mean PI at 3 months (M3) and number of potentially treatment-related adverse events (TRAEs). Secondary outcomes included Western Ontario MAC Master University function subscale (range, 0–68), additional pain and quality of life measures, and responder rates. Results: The non-inferiority of W-TENS was demonstrated in both the per protocol (PP) and intent-to-treat (ITT) populations. At M3, PI in PP population was 3.87 (2.12) compared with 4.66 (2.37) [delta: −0.79 (0.44); 95% CI (−1.65, 0.08)] in W-TENS and WO groups, respectively. A planned superiority analysis showed a significant superiority of W-TENS over WO on PI at M3 (p = 0.0124). The number of TRAEs was significantly lower in the W-TENS group (n = 7) than in the WO group (n = 36) (p < 0.001). Other secondary outcomes also favored W-TENS. Conclusion: W-TENS was more effective and better tolerated than WO in the treatment of chronic nociceptive KOA pain and offers an interesting non-pharmacological analgesic alternative in the management of KOA. Trial Registration: ClinicalTrials.gov: NCT03902340 [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

73. 2018 update of the EULAR recommendations for the management of hand osteoarthritis

Author

Kloppenburg, Margreet, primary, Kroon, Féline PB, additional, Blanco, Francisco J, additional, Doherty, Michael, additional, Dziedzic, Krysia S, additional, Greibrokk, Elsie, additional, Haugen, Ida K, additional, Herrero-Beaumont, Gabriel, additional, Jonsson, Helgi, additional, Kjeken, Ingvild, additional, Maheu, Emmanuel, additional, Ramonda, Roberta, additional, Ritt, Marco JPF, additional, Smeets, Wilma, additional, Smolen, Josef S, additional, Stamm, Tanja A, additional, Szekanecz, Zoltan, additional, Wittoek, Ruth, additional, and Carmona, Loreto, additional

Published
2018
Full Text
View/download PDF

74. Erratum to: The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology (Rheumatology International, (2017), 37, 8, (1227-1236), 10.1007/s00296-017-3700-y)

Author

Migliore, Alberto, Scirè, Carlo Alberto, Carmona, Loreto, Herrero-Beaumont, Gabriel, Bizzi, Emanuele, Branco, Jaime, Carrara, Greta, Chevalier, Xavier, Collaku, Ledio, Aslanidis, Spiros, Denisov, Lev, Di Matteo, Luigi, Bianchi, Gerolamo, Diracoglu, Demirhan, Frediani, Bruno, Maheu, Emmanuel, Martusevich, Natalia, Bagnato, Gian Filippo, Scarpellini, Magda, Minisola, Giovanni, Akkoc, Nurullah, Ramonda, Roberta, Barskova, Tatiana, Babic-Naglic, Durda, Muelas, Jose Vicente Moreno, Ionescu, Ruxandra, Rashkov, Rasho, Damjanov, Nemanja, and Cerinic, Marco Matucci

Subjects
Rheumatology, Immunology and Allergy, Immunology, NO
Published
2017

76. Additional file 1: Table S1. of Aesthetic discomfort in hand osteoarthritis: results from the LIège Hand Osteoarthritis Cohort (LIHOC)

Author

Neuprez, Audrey, Bruyère, Olivier, Maheu, Emmanuel, Dardenne, Nadia, Nansa Burlet, D’Hooghe, Pieter, Distèche, Stéphan, and Jean-Yves Reginster

Subjects
macromolecular substances
Abstract

Radiological severity and impact of hand osteoarthritis on functional disability, health-related quality of life, and psychological status. (DOC 38 kb)

Published
2015
Full Text
View/download PDF

77. Additional file 2: Table S2. of Aesthetic discomfort in hand osteoarthritis: results from the LIège Hand Osteoarthritis Cohort (LIHOC)

Author

Neuprez, Audrey, Bruyère, Olivier, Maheu, Emmanuel, Dardenne, Nadia, Nansa Burlet, D’Hooghe, Pieter, Distèche, Stéphan, and Jean-Yves Reginster

Subjects
cardiovascular system, cardiovascular diseases, circulatory and respiratory physiology
Abstract

Characteristics of patients reporting high (HAD) or low (LAD) (aesthetic discomfort). (DOC 55 kb)

Published
2015
Full Text
View/download PDF

78. Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis

Author

Reginster, Jean Yves, Cooper, Cyrus, Hochberg, Marc, Pelletier, Jean Pierre, Rizzoli, René, Kanis, John, Abadie, Eric, Maheu, Emmanuel, Brandi, Maria Luisa, Devogelaer, Jean Pierre, Branco, Jaime, Herrero-Beaumont, Gabriel, D'Hooghe, Pieter, Bruyère, Olivier, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Centro de Estudos de Doenças Crónicas (CEDOC)

Subjects
Medicine(all), Glucosamine, Hyaluronic acid, Osteoarthritis, ddc:618.97, Chondroitin, Symptomatic slow-acting drugs in osteoarthritis
Abstract

Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthritis, the American College of Rheumatology (ACR) guidelines (concerning also hip and hand osteoarthritis) and the algorithm recommendations by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). This is particularly evident for the drug class of symptomatic slow-acting drugs in osteoarthritis. In this paper, we highlight these differences and try to understand where they derive from, proposing an evidence-based interpretation. publishersversion published

Published
2015

80. French law: what about a reasoned reimbursement of serum vitamin D assays?

Author

Souberbielle, Jean-Claude, additional, Benhamou, Claude Laurent, additional, Cortet, Bernard, additional, Rousière, Mickael, additional, Roux, Christian, additional, Abitbol, Vered, additional, Annweiler, Cédric, additional, Audran, Maurice, additional, Bacchetta, Justine, additional, Bataille, Pierre, additional, Beauchet, Olivier, additional, Bardet, Rémi, additional, Benachi, Alexandra, additional, Berenbaum, Francis, additional, Blain, Hubert, additional, Borson-Chazot, Françoise, additional, Breuil, Véronique, additional, Briot, Karine, additional, Brunet, Philippe, additional, Carel, Jean-Claude, additional, Caron, Philippe, additional, Chabre, Olivier, additional, Chanson, Philippe, additional, Chapurlat, Roland, additional, Cochat, Pierre, additional, Coutant, Régis, additional, Christin-Maitre, Sophie, additional, Cohen-Solal, Martine, additional, Combe, Christian, additional, Cormier, Catherine, additional, Courbebaisse, Marie, additional, Debrus, Grégory, additional, Delemer, Brigitte, additional, Deschenes, Georges, additional, Duquenne, Marc, additional, Duval, Guillaume, additional, Fardellone, Patrice, additional, Fouque, Denis, additional, Friedlander, Gérard, additional, Gauvain, Jean-Bernard, additional, Groussin, Lionel, additional, Guggenbuhl, Pascal, additional, Houillier, Pascal, additional, Hannedouche, Thierry, additional, Jacot, William, additional, Javier, Rose-Marie, additional, Jean, Guillaume, additional, Jeandel, Claude, additional, Joly, Dominique, additional, Kamenicky, Peter, additional, Knebelmann, Bertrand, additional, Lafage-Proust, Marie-Hélène, additional, LeBouc, Yves, additional, Legrand, Erick, additional, Levy-Weil, Florence, additional, Linglart, Agnès, additional, Machet, Laurent, additional, Maheu, Emmanuel, additional, Mallet, Eric, additional, Marcelli, Christian, additional, Marès, Pierre, additional, Mariat, Christophe, additional, Maruani, Gérard, additional, Maugars, Yves, additional, Montagnon, France, additional, Moulin, Bruno, additional, Orcel, Philippe, additional, Partouche, Henri, additional, Personne, Virginie, additional, Pierrot-Deseilligny, Charles, additional, Polak, Michel, additional, Pouteil-Noble, Claire, additional, Prié, Dominique, additional, Raynaud-Simon, Agathe, additional, Rolland, Yves, additional, Sadoul, Jean-Louis, additional, Salle, Bernard, additional, Sault, Corinne, additional, Schott, Anne-Marie, additional, Sermet-Gaudelus, Isabelle, additional, Soubrier, Martin, additional, Tack, Ivan, additional, Thervet, Eric, additional, Tostivint, Isabelle, additional, Touraine, Philippe, additional, Tremollières, Florence, additional, Urena-Torres, Pablo, additional, Viard, Jean-Paul, additional, Wemeau, Jean-Louis, additional, Weryha, Georges, additional, Winer, Norbert, additional, Young, Jacques, additional, and Thomas, Thierry, additional

Published
2016
Full Text
View/download PDF

81. Response to: ‘Does the prevalence of radiographic hand osteoarthritis in patients with HIV-1 infection increase or not?’ by Luoet al

Author

Sellam, Jérémie, primary, Lacombe, Karine, additional, Tomi, Anne-Laurence, additional, Haugen, Ida K, additional, Felson, David T, additional, Fellahi, Soraya, additional, Bastard, Jean-Philippe, additional, Miquel, Anne, additional, Sebire, Manuela, additional, Rey-Jouvin, Caroline, additional, Maheu, Emmanuel, additional, Capeau, Jacqueline, additional, Girard, Pierre-Marie, additional, Meynard, Jean-Luc, additional, and Berenbaum, Francis, additional

Published
2016
Full Text
View/download PDF

82. Increased prevalence and severity of radiographic hand osteoarthritis in patients with HIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study

Author

Tomi, Anne-Laurence, primary, Sellam, Jérémie, additional, Lacombe, Karine, additional, Fellahi, Soraya, additional, Sebire, Manuela, additional, Rey-Jouvin, Caroline, additional, Miquel, Anne, additional, Bastard, Jean-Philippe, additional, Maheu, Emmanuel, additional, Haugen, Ida K, additional, Felson, David T, additional, Capeau, Jacqueline, additional, Girard, Pierre-Marie, additional, Berenbaum, Francis, additional, and Meynard, Jean-Luc, additional

Published
2016
Full Text
View/download PDF

83. Ostéopathies fragilisantes, maladie rénale chronique, malabsorptions, anomalies biologiques du métabolisme phosphocalcique : les bonnes indications pour un remboursement raisonné du dosage de vitamine D [Weakening osteopathies, chronic kidney disease, malabsorption, biological anomalies of calium/phosphorus metabolism: appropriate indications for a reasoned reimbursment of serum vitamin D measurement]

Author

Souberbielle, Jean-Claude, Benhamou, Claude-Laurent, Cortet, Bernard, Rousière, Mickael, Roux, Christian, Abitbol, Vered, Annweiler, Cédric, Audran, Maurice, Bacchetta, Justine, Bataille, Pierre, Beauchet, Olivier, Bardet, Rémi, Benachi, Alexandra, Berenbaum, Francis, Blain, Hubert, Borson-Chazot, Françoise, Breuil, Véronique, Briot, Karine, Brunet, Philippe, Carel, Jean-Claude, Caron, Philippe, Chabre, Olivier, Chanson, Philippe, Chapurlat, Roland, Cochat, Pierre, Coutant, Régis, Christin-Maitre, Sophie, Cohen-Solal, Martine, Combe, Christian, Cormier, Catherine, Courbebaisse, Marie, Debrus, Grégory, Delemer, Brigitte, Deschênes, Georges, Duquenne, Marc, Fardellone, Patrice, Fouque, Denis, Friedlander, Gérard, Gauvain, Jean-Bernard, Groussin, Lionel, Guggenbuhl, Pascal, Houillier, Pascal, Hannedouche, Thierry, Jacot, William, Javier, Rose-Marie, Jean, Guillaume, Jeandel, Claude, Joly, Dominique, Kamenicky, Peter, Knebelmann, Bertrand, Lafage-Proust, Marie-Hélène, Lebouc, Yves, Legrand, Erick, Levy-Weil, Florence, Linglart, Agnès, Machet, Laurent, Maheu, Emmanuel, Mallet, Eric, Marcelli, Christian, Mares, Pierre, Mariat, Christophe, Maruani, Gérard, Maugars, Yves, Montagnon, France, Moulin, Bruno, Orcel, Philippe, Partouche, Henri, Personne, Virginie, Pierrot-Deseilligny, Charles, Polak, Michel, Pouteil-Noble, Claire, Prié, Dominique, Raynaud-Simon, Agathe, Rolland, Yves, Sadoul, Jean-Louis, Salle, Bernard, Sault, Corinne, Schott, Anne-Marie, Sermet-Gaudelus, Isabelle, Soubrier, Martin, Tack, Ivan, Thervet, Eric, Tostivint, Isabelle, Touraine, Philippe, Trémollières, Florence, Urena-Torres, Pablo, Viard, Jean-Paul, Wemeau, Jean-Louis, Weryha, Georges, Winer, Norbert, Young, Jacques, Thomas, Thierry, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie[Lille], Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Cochin [AP-HP], Département de gastroentérologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de médecine interne et gérontologie clinique [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Groupe d'Études Remodelage Osseux et bioMatériaux (GEROM), Université d'Angers (UA), COREVIH Nord Pas-de-Calais, Centre Hospitalier de Tourcoing, Néphrologie Hémodialyse, Centre hospitalier de Boulogne sur mer, Département de Médecine Interne et Gérontologie clinique, Centre Hospitalier Universitaire d'Angers (CHU Angers), Service de gynécologie-obstétrique, médecine de la reproduction [Béclère], Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Euromov (EuroMov), Université de Montpellier (UM), Eq 4, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Groupement Hospitalier Lyon-Est (GHE), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Centre de médecine nucléaire, Fédération d'endocrinologie-Groupement hospitalier Lyon-Est-Fédération d'endocrinologie-Groupement hospitalier Lyon-Est, Service de rhumatologie, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet, Caractérisation du Tissu Osseux par Imagerie : techniques et applications, Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Neuroprotection du Cerveau en Développement / Promoting Research Oriented Towards Early Cns Therapies (PROTECT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7), Service d'Endocrinologie Diabétologie Pédiatrique et Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Hôpital Robert Debré, Service d'Endocrinologie (TOULOUSE - Endocrino), CHU Toulouse [Toulouse], Biologie du Cancer et de l'Infection (BCI ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Récepteurs stéroïdiens : physiopathologie endocrinienne et métabolique, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR93-Université Paris-Sud - Paris 11 (UP11), Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases (LYOS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Pédiatrie, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Endocrinologie pédiatrique[CHU Angers], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Physiopathologie des maladies génétiques d'expression pédiatrique, Os et articulations, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fibrose hépatique et cancer du foie, Université Bordeaux Segalen - Bordeaux 2-IFR66-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie-transplantation-dialyse [Bordeaux], CHU Bordeaux [Bordeaux], Centre de recherche Croissance et signalisation (UMR_S 845), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Néphrologie, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service d'Endocrinologie - Diabète - Nutrition [Reims], Université de Reims Champagne-Ardenne (URCA)-Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Unité de Néphrologie Pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré, Mécanismes physiologiques et conséquences des calcifications cardiovasculaires: rôle des remodelages cardiovasculaires et osseux, Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de médecine gériatrique, Centre Hospitalier Régional d'Orléans (CHRO), Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de rhumatologie [Rennes] = Rheumatology [Rennes], CHU Pontchaillou [Rennes], Service de Physiologie [Georges-Pompidou], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5), Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université Montpellier 1 (UM1), Centre de Lutte contre le Cancer, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER-UNICANCER-CHU Clermont-Ferrand, Service d'Endocrinologie et Maladies de la reproduction, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Tissu Osseux et Contraintes Mecaniques (LBTO), Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunologie et génétique du diabète de type 1, génétique multifactorielle en endocrinologie pédiatrique (U986), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de référence des maladies rares du calcium et du phosphore, CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de Rhumatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de gynécologie obstétrique, Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Rhumatologie, Hôtel-Dieu, Service de Néphrologie et Transplantation, CHU Strasbourg, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de néphrologie et transplantation, Gérontopôle, Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse], Service d'Endocrinologie (NICE - Endocrino), Centre Hospitalier Universitaire de Nice (CHU Nice), Département d'information médicale, Hospices Civils de Lyon (HCL)-Université de Lyon, CHU Clermont-Ferrand, CHU Gabriel Montpied [Clermont-Ferrand], Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Service des explorations physiologiques, CHU Toulouse [Toulouse]-Hôpital de Rangueil, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-CHU Necker - Enfants Malades [AP-HP], CHU Pitié-Salpêtrière [AP-HP], Université Pierre et Marie Curie - Paris 6 (UPMC), Centre de ménopause, Hôpital Paule de Viguier, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Centre de Diagnost ic et de Thérapeutique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu, Service d'Endocrinologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Gynécologie Obstétrique (NANTES - Gynéco Obstétrique), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut Gustave Roussy (IGR), Service d'endocrinologie, PRES Université Nantes Angers Le Mans (UNAM), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL), Centre Hospitalier Boulogne-sur-mer, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Endocrinologie, maladies métaboliques et nutrition [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Nutrition [Cergy] (N - cabinet libéral ), Centre Hospitalier Le Mans (CH Le Mans), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre de Rein Artificiel [Tassin la demi-lune] (CRA), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Victor Dupouy, Normandie Université (NU), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Cabinet de Rhumatologie [Saint-Etienne] (CdR), Hôpital Lariboisière-Fernand-Widal [APHP], Département de Médecine Générale, Université Paris Cité (UPCité), CIC Hôpital Bichat, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine, Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Académie nationale de médecine, Eurofins Biomnis, Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Obstétrique [CHU Toulouse], Pôle Femme-Mère-Couple [CHU Toulouse], Clinique du Landy [Saint-Ouen] (CL), Hôpital Hôtel-Dieu [Paris], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Lyon-Est (GHE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Picardie Jules Verne (UPJV), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), CHU Cochin [AP-HP], Université d'Angers ( UA ) -CHU Angers, Remodelage osseux et biomatériaux, Université d'Angers ( UA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Angers, Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Antoine Béclère, Centre de Recherche Saint-Antoine ( CR Saint-Antoine ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Department of Geriatrics - Efficiency and Deficiency Laboratory, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Groupement Hospitalier Lyon-Est ( GHE ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ) -Centre de médecine nucléaire, CHU Nice-Hôpital l'Archet, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Hôpital de la Conception [CHU - APHM] ( LA CONCEPTION ), Promoting Research Oriented Towards Early Cns Therapies ( PROTECT ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Diderot - Paris 7 ( UPD7 ), Service d'Endocrinologie ( TOULOUSE - Endocrino ), Biologie du Cancer et de l'Infection ( BCI - UMR S1036 ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Grenoble Alpes ( UGA ), Université Paris-Sud - Paris 11 ( UP11 ) -IFR93-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases ( LYOS ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Diabétologie et Endocrinologie de la Reproduction, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Bordeaux Segalen - Bordeaux 2-IFR66-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de recherche Croissance et signalisation ( UMR_S 845 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Université de Reims Champagne-Ardenne ( URCA ) -Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims ( CHU Reims ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré, Université de Picardie Jules Verne ( UPJV ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Cardiovasculaire, métabolisme, diabétologie et nutrition ( CarMeN ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hospices Civils de Lyon ( HCL ) -Institut National des Sciences Appliquées de Lyon ( INSA Lyon ), Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Institut National de la Recherche Agronomique ( INRA ), Centre Hospitalier Régional d'Orléans ( CHR ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Hôpital Sud, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Université Paris Descartes - Paris 5 ( UPD5 ), Institut de recherche en cancérologie de Montpellier ( IRCM - U896 Inserm - UM1 ), Université Montpellier 1 ( UM1 ) -CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Centre de gérontologie clinique, Université Montpellier 1 ( UM1 ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), CHU Clermont-Ferrand-Centre Jean Perrin, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Tissu Osseux et Contraintes Mecaniques ( LBTO ), Université Jean Monnet [Saint-Étienne] ( UJM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Immunologie et génétique du diabète de type 1, génétique multifactorielle en endocrinologie pédiatrique ( U986 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), AP-HP, Service de Rhumatologie, CHU Saint-Antoine [APHP], CHU Caen, Hôpital Universitaire Carémeau [Nîmes], Service de néphrologie et tranplantation, CHU Saint-Etienne-Hôpital nord, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université de Lyon-Université de Lyon-Hospices Civils de Lyon ( HCL ) -Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ), Gérontopôle de Toulouse, Service d'Endocrinologie ( NICE - Endocrino ), CHU Nice, Hospices Civils de Lyon ( HCL ) -Université de Lyon, CHU Gabriel Montpied ( CHU ), Institut des Maladies Métaboliques et Cardiovasculaires ( I2MC ), Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -CHU Necker - Enfants Malades [AP-HP], Department of Endocrinology and Reproductive Medicine, CHU Pitié-Salpêtrière [APHP]-Centre de Référence des Maladies Endocriniennes rares de la croissance et des maladies gynécologiques rares, Université Pierre et Marie Curie - Paris 6 ( UPMC ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôtel-Dieu, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Service de Gynécologie Obstétrique ( NANTES - Gynéco Obstétrique ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), Institut Gustave Roussy ( IGR ), Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Antoine Béclère, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Groupement Hospitalier Lyon-Est (GHE), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Robert Debré, Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Centre Hospitalier Régional d'Orléans (CHR), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], CHU Gabriel Montpied (CHU), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-CHU Necker - Enfants Malades [AP-HP], CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôtel-Dieu, and Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre

Subjects
MESH: Bone Diseases / blood, Calcium Metabolism Disorders / blood, Humans, Malabsorption Syndromes / blood, Phosphorus Metabolism Disorders / blood, Renal Insufficiency, Chronic / blood, Vitamin D / blood, [ SDV ] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], MathematicsofComputing_GENERAL, Phosphorus Metabolism Disorders, [SDV.CAN]Life Sciences [q-bio]/Cancer, GeneralLiterature_MISCELLANEOUS, InformationSystems_GENERAL, Malabsorption Syndromes, Calcium Metabolism Disorders, Renal Insufficiency, Chronic, Vitamin D, Bone Diseases, ComputingMilieux_MISCELLANEOUS
Abstract

National audience; No abstract available

Published
2014
Full Text
View/download PDF

84. 2018 update of the EULAR recommendations for the management of hand osteoarthritis.

Author

Kloppenburg, Margreet, Kroon, Féline P. B., Blanco, Francisco J., Doherty, Michael, Dziedzic, Krysia S., Greibrokk, Elsie, Haugen, Ida K., Herrero-Beaumont, Gabriel, Jonsson, Helgi, Kjeken, Ingvild, Maheu, Emmanuel, Ramonda, Roberta, Ritt, Marco J. P. F., Smeets, Wilma, Smolen, Josef S., Stamm, Tanja A., Szekanecz, Zoltan, Wittoek, Ruth, Carmona, Loreto, and Kroon, Féline Pb

Abstract

Since publication of the European League Against Rheumatism (EULAR) recommendations for management of hand osteoarthritis (OA) in 2007 new evidence has emerged. The aim was to update these recommendations. EULAR standardised operating procedures were followed. A systematic literature review was performed, collecting the evidence regarding all non-pharmacological, pharmacological and surgical treatment options for hand OA published to date. Based on the evidence and expert opinion from an international task force of 19 physicians, healthcare professionals and patients from 10 European countries formulated overarching principles and recommendations. Level of evidence, grade of recommendation and level of agreement were allocated to each statement. Five overarching principles and 10 recommendations were agreed on. The overarching principles cover treatment goals, information provision, individualisation of treatment, shared decision-making and the need to consider multidisciplinary and multimodal (non-pharmacological, pharmacological, surgical) treatment approaches. Recommendations 1-3 cover different non-pharmacological treatment options (education, assistive devices, exercises and orthoses). Recommendations 4-8 describe the role of different pharmacological treatments, including topical treatments (preferred over systemic treatments, topical non-steroidal anti-inflammatory drugs (NSAIDs) being first-line choice), oral analgesics (particularly NSAIDs to be considered for symptom relief for a limited duration), chondroitin sulfate (for symptom relief), intra-articular glucocorticoids (generally not recommended, consider for painful interphalangeal OA) and conventional/biological disease-modifying antirheumatic drugs (discouraged). Considerations for surgery are described in recommendation 9. The last recommendation relates to follow-up. The presented EULAR recommendations provide up-to-date guidance on the management of hand OA, based on expert opinion and research evidence. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

85. Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Reginster, Jean-Yves, Cooper, Cyrus, Hochberg, Marc, Pelletier, Jean-Pierre, Rizzoli, René, Kanis, John, Abadie, Eric, Maheu, Emmanuel, Brandi, Maria Luisa, Devogelaer, Jean-Pierre, Branco, Jaime, Herrero-Beaumont, Gabriel, D'Hooghe, Pieter, Bruyère, Olivier, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Reginster, Jean-Yves, Cooper, Cyrus, Hochberg, Marc, Pelletier, Jean-Pierre, Rizzoli, René, Kanis, John, Abadie, Eric, Maheu, Emmanuel, Brandi, Maria Luisa, Devogelaer, Jean-Pierre, Branco, Jaime, Herrero-Beaumont, Gabriel, D'Hooghe, Pieter, and Bruyère, Olivier

Abstract

Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthritis, the American College of Rheumatology (ACR) guidelines (concerning also hip and hand osteoarthritis) and the algorithm recommendations by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). This is particularly evident for the drug class of symptomatic slow-acting drugs in osteoarthritis. In this paper, we highlight these differences and try to understand where they derive from, proposing an evidence-based interpretation.

Published
2015

88. Weakening osteopathies, chronic kidney disease, malabsorption, biological anomalies of calium/phosphorus metabolism: appropriate indications for a reasoned reimbursment of serum vitamin D measurement

Author

Souberbielle, Jean-Claude, additional, Benhamou, Claude Laurent, additional, Cortet, Bernard, additional, Rousière, Mickael, additional, Roux, Christian, additional, Abitbol, Vered, additional, Annweiler, Cédric, additional, Audran, Maurice, additional, Bacchetta, Justine, additional, Bataille, Pierre, additional, Beauchet, Olivier, additional, Bardet, Rémi, additional, Benachi, Alexandra, additional, Berenbaum, Francis, additional, Blain, Hubert, additional, Borson-Chazot, Françoise, additional, Breuil, Véronique, additional, Briot, Karine, additional, Brunet, Philippe, additional, Carel, Jean-Claude, additional, Caron, Philippe, additional, Chabre, Olivier, additional, Chanson, Philippe, additional, Chapurlat, Roland, additional, Cochat, Pierre, additional, Coutant, Régis, additional, Christin-Maitre, Sophie, additional, Cohen-Solal, Martine, additional, Combe, Christian, additional, Cormier, Catherine, additional, Courbebaisse, Marie, additional, Debrus, Grégory, additional, Delemer, Brigitte, additional, Deschenes, Georges, additional, Duquenne, Marc, additional, Fardellone, Patrice, additional, Fouque, Denis, additional, Friedlander, Gérard, additional, Gauvain, Jean-Bernard, additional, Groussin, Lionel, additional, Guggenbuhl, Pascal, additional, Houillier, Pascal, additional, Hannedouche, Thierry, additional, Jacot, William, additional, Javier, Rose-Marie, additional, Jean, Guillaume, additional, Jeandel, Claude, additional, Joly, Dominique, additional, Kamenicky, Peter, additional, Knebelmann, Bertrand, additional, Lafage-Proust, Marie-Hélène, additional, LeBouc, Yves, additional, Legrand, Erick, additional, Levy-Weil, Florence, additional, Linglart, Agnès, additional, Machet, Laurent, additional, Maheu, Emmanuel, additional, Mallet, Eric, additional, Marcelli, Christian, additional, Marès, Pierre, additional, Mariat, Christophe, additional, Maruani, Gérard, additional, Maugars, Yves, additional, Montagnon, France, additional, Moulin, Bruno, additional, Orcel, Philippe, additional, Partouche, Henri, additional, Personne, Virginie, additional, Pierrot-Deseilligny, Charles, additional, Polak, Michel, additional, Pouteil-Noble, Claire, additional, Prié, Dominique, additional, Raynaud-Simon, Agathe, additional, Rolland, Yves, additional, Sadoul, Jean-Louis, additional, Salle, Bernard, additional, Sault, Corinne, additional, Schott, Anne-Marie, additional, Sermet-Gaudelus, Isabelle, additional, Soubrier, Martin, additional, Tack, Ivan, additional, Thervet, Éric, additional, Tostivint, Isabelle, additional, Touraine, Philippe, additional, Tremollières, Florence, additional, Urena-Torres, Pablo, additional, Viard, Jean-Paul, additional, Wemeau, Jean-Louis, additional, Weryha, Georges, additional, Winer, Norbert, additional, Young, Jacques, additional, and Thomas, Thierry, additional

Published
2014
Full Text
View/download PDF

89. Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non-inferiority, prospective, randomised, controlled trial

Author

Maheu, Emmanuel, Zaim, Mohammed, Appelboom, Thierry, Jeka, Slawonir, Trc, Tomáš, Maasalu, Katre, Berenbaum, Francis, Maheu, Emmanuel, Zaim, Mohammed, Appelboom, Thierry, Jeka, Slawonir, Trc, Tomáš, Maasalu, Katre, and Berenbaum, Francis

Abstract

Objectives: To compare the efficacy and safety of a "medium" molecular weight (MW) hyaluronan product (F60027, Structovial®) with a "high" MW (Hylan G-F20, Synvisc®). Methods: Prospective, randomised, multicentre, double-blind, active controlled, parallel-group study with a non-inferiority design. Patients with symptomatic KOA, global pain ≥40 mm (VAS, 0-100), Lequesne index (LFI, 0-24) score >7 and radiological Kellgren-Lawrence grade 2/3 were centrally randomised to receive F60027 or Hylan G-F20, administered via three weekly injections, with regular follow-up evaluations up to week 24 (W24). The primary outcome was LFI score change over 24 weeks. Secondary outcomes comprised pain VAS, quality of life, patient's and physician's global assessments, rescue medication consumption and OMERACT-OARSI responders rate. Results: 276 patients were analysed in the full analysis dataset (FAS), 236 in the Per Protocol dataset (PP). In the main efficacy analysis (PP), the difference of the LFl score change over 24 weeks between F60027 (-4.67 (0.27)) and Hylan G-F20 (-4.54 (0.28)) was 0.132 [95%CI: -0.598, 0.861 J which met the predefined non-inferiority margin. Analyses of secondary efficacy criteria showed clinically relevant improvements of all outcomes at W24 for each treatment on both PPIFAS populations. Changes of LFI score between baseline and W24 were -5.73 in the F60027 and -5.57 in the Hylan G-F20 group (PP dataset). Few local reactions were reported: 3.6% of patients in each group. Conclusion: F60027 and Hylan G-F20 were equally effective in reducing functional impairment and relieving pain in KOA patients, and well-tolerated. © Copyright Clinical and Experimental Rheumatology 2011., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2011

92. Randomised, controlled trial of avocado–soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study

Author

Maheu, Emmanuel, primary, Cadet, Christian, additional, Marty, Marc, additional, Moyse, Dominique, additional, Kerloch, Isabelle, additional, Coste, Philippe, additional, Dougados, Maxime, additional, Mazières, Bernard, additional, Spector, Tim D, additional, Halhol, Hafid, additional, Grouin, Jean-Marie, additional, and Lequesne, Michel, additional

Published
2013
Full Text
View/download PDF

93. MRI and serum biomarkers correlate with radiographic features in painful hand osteoarthritis

Author

Roux, Christian, Foltz, Violaine, Maheu, Emmanuel, Baron, Gabriel, Gandjbakhch, Frederique, Lukas, Cedric, Wendling, Daniel, Loeuille, Damien, Lafforgue, Pierre, Euler-Ziegler, Liana, Richette, Pascal, Chevalier, Xavier, on Osteoarthritis, French Section, HELLE, Déborah, CHU Nice, Hopital l'Archet 1, Centre Hospitalier Universitaire de Nice (CHU Nice), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Département d'épidémiologie, biostatistique et recherche clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Rhumatologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Rhumatologie [Sainte- Marguerite - APHM] ( Hôpitaux Sud), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Hôpital Lariboisière, Université Paris Diderot - Paris 7 (UPD7)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Rhumatologie [CHU Lariboisière], Hôpital Lariboisière-Fernand-Widal [APHP], Service de Rhumatologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Service de Rhumatologie [CHRU de Besançon], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7)

Subjects
Male, Hand Joints, Interleukin-6, Tumor Necrosis Factor-alpha, [SDV]Life Sciences [q-bio], Interleukin-1beta, education, Cartilage Oligomeric Matrix Protein, Middle Aged, Magnetic Resonance Imaging, Severity of Illness Index, [SDV] Life Sciences [q-bio], C-Reactive Protein, Osteoarthritis, Humans, Female, Hyaluronic Acid, Biomarkers, health care economics and organizations, Aged, Interleukin-1
Abstract

To explore the relationship between clinical findings, biologic biomarkers, conventional radiography and MRI in patients with painful hand OA.The following patient baseline data from the DORA study (evaluating anti-TNF-α agents against painful hand OA) were used: clinical assessment (pain, swelling, stiffness and function: Dreiser functional hand index [FIHOA] and Cochin hand functional scale [CHFS]); measurement of biomarkers (cartilage oligomeric matrix protein (COMP), type IIA collagen N-propeptid (PIINP), hyaluronic acid (HA), ultrasensitive C-reactive protein (usCRP), tumour necrosis factor (TNF), interleukin (IL)-6, IL-1β and urinary CTXII); radiological staging (Verbruggen, Kallman, Kellgren-Lawrence); anatomical evaluation by contrast-enhanced MRI of proximal and distal interphalangeal joints of dominant hand. Associations between clinical, biomarker and imaging findings were assessed using the Spearman correlation coefficient and test.18 patients were recruited, and 144 joints studied. A correlation was found between clinical features (pain, FIHOA, CHFS) and the Verbruggen score (respectively: p=0.05, r=0.47; p=0.05, r=0.48; p=0.05, r=0.48). Serum IL-1 level was strongly associated with loss of function (FIHOA: p=0.02, r=-0.73; CHFS: p=0.01, r=-0.76) and radiological erosions (p=0.03, r=0.7) as with urinary CTX2. A significant association was found between MRI osteophytes and usCRP (p=0.0026). MRI and radiological features were significantly correlated except for synovitis and bone marrow lesions.MRI synovitis was not correlated with radiological scores, clinical or biologic markers of inflammation. There was a strong correlation between other MRI features and radiological scores. Serum IL-1 level was associated with structural damage and function.

Published
1996

99. Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versusweak opioids

Author

Maheu, Emmanuel, Soriot-Thomas, Sandrine, Noel, Eric, Ganry, Hervé, Lespessailles, Eric, and Cortet, Bernard

Abstract

Introduction: Despite their poor tolerance, especially in the elderly, weak opioids (WO) remain commonly prescribed for patients with knee osteoarthritis (KOA). We compared the efficacy and safety of a new wearable transcutaneous electrical nerve stimulation (W-TENS) device with WO for the treatment of moderate-to-severe, nociceptive KOA chronic pain.Methods: The study was a non-inferiority, multicentric, prospective, randomized, single-blind, controlled, 2-parallel groups Trial. A total of 110 patients with KOA were included (Kellgren-Lawrence radiographic grade ⩾2; American College of Rheumatology criteria), with chronic moderate-to-severe nociceptive pain (mean 8-day pain intensity (PI) ⩾ 4 on an 11-point numerical rating scale), in failure to non-opioid analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs). Patients with neuropathic pain were excluded. The co-primary endpoints were mean PI at 3 months (M3) and number of potentially treatment-related adverse events (TRAEs). Secondary outcomes included Western Ontario MAC Master University function subscale (range, 0–68), additional pain and quality of life measures, and responder rates.Results: The non-inferiority of W-TENS was demonstrated in both the per protocol (PP) and intent-to-treat (ITT) populations. At M3, PI in PP population was 3.87 (2.12) compared with 4.66 (2.37) [delta: −0.79 (0.44); 95% CI (−1.65, 0.08)] in W-TENS and WO groups, respectively. A planned superiority analysis showed a significant superiority of W-TENS over WO on PI at M3 (p= 0.0124). The number of TRAEs was significantly lower in the W-TENS group (n= 7) than in the WO group (n= 36) (p< 0.001). Other secondary outcomes also favored W-TENS.Conclusion: W-TENS was more effective and better tolerated than WO in the treatment of chronic nociceptive KOA pain and offers an interesting non-pharmacological analgesic alternative in the management of KOA. Trial Registration:ClinicalTrials.gov: NCT03902340

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results